Xu You-Fen, Autio Dawn, Rheuben Mary B, Atchison William D
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824-1317, USA.
J Neurophysiol. 2002 Dec;88(6):3243-58. doi: 10.1152/jn.00934.2001.
Chronic treatment of rodents with 2,4-dithiobiuret (DTB) induces a neuromuscular syndrome of flaccid muscle weakness that mimics signs seen in several human neuromuscular disorders such as congenital myasthenic syndromes, botulism, and neuroaxonal dystrophy. DTB-induced muscle weakness results from a reduction of acetylcholine (ACh) release by mechanisms that are not yet clear. The objective of this study was to determine if altered release of ACh during DTB-induced muscle weakness was due to impairments of synaptic vesicle exocytosis, endocytosis, or internal vesicular processing. We examined motor nerve terminals in the triangularis sterni muscles of DTB-treated mice at the onset of muscle weakness. Uptake of FM1-43, a fluorescent marker for endocytosis, was reduced to approximately 60% of normal after either high-frequency nerve stimulation or K(+) depolarization. Terminals ranged from those with nearly normal fluorescence ("bright terminals") to terminals that were poorly labeled ("dim terminals"). Ultrastructurally, the number of synaptic vesicles that were labeled with horseradish peroxidase (HRP) was also reduced by DTB to approximately 60%; labeling among terminals was similarly variable. A subset of DTB-treated terminals having abnormal tubulovesicular profiles in their centers did not respond to stimulation with increased uptake of HRP and may correspond to dim terminals. Two findings suggest that posttetanic "slow endocytosis" remained qualitatively normal: the rate of this type of endocytosis as measured with FM1-43 did not differ from normal, and HRP was observed in organelles associated with this pathway- coated vesicles, cisternae, as well as synaptic vesicles but not in the tubulovesicular profiles. In DTB-treated bright terminals, end-plate potential (EPP) amplitudes were decreased, and synaptic depression in response to 15-Hz stimulation was increased compared with those of untreated mice; in dim terminals, EPPs were not observed during block with D-tubocurarine. Nerve-stimulation-induced unloading of FM1-43 was slower and less complete than normal in bright terminals, did not occur in dim terminals, and was not enhanced by alpha-latrotoxin. Collectively, these results indicate that the size of the recycling vesicle pool is reduced in nerve terminals during DTB-induced muscle weakness. The mechanisms by which this reduction occurs are not certain, but accumulated evidence suggests that they may include defects in either or both exocytosis and internal vesicular processing.
用2,4 - 二硫代双缩脲(DTB)对啮齿动物进行长期治疗会诱发一种弛缓性肌无力的神经肌肉综合征,该综合征类似于在几种人类神经肌肉疾病中所见的体征,如先天性肌无力综合征、肉毒中毒和神经轴索性营养不良。DTB诱导的肌无力是由乙酰胆碱(ACh)释放减少所致,其机制尚不清楚。本研究的目的是确定DTB诱导肌无力期间ACh释放改变是否归因于突触小泡胞吐、内吞或泡内加工过程的损伤。我们在肌无力发作时检查了DTB处理小鼠胸骨三角肌中的运动神经末梢。在高频神经刺激或K⁺去极化后,内吞荧光标记物FM1 - 43的摄取减少至正常水平的约60%。神经末梢范围从荧光几乎正常的(“亮末梢”)到标记较差的(“暗末梢”)。超微结构上,用辣根过氧化物酶(HRP)标记的突触小泡数量也被DTB减少至约60%;末梢间的标记同样存在差异。DTB处理的末梢中,有一部分在其中心具有异常的微管泡结构,对刺激无反应,HRP摄取未增加,可能对应于暗末梢。有两个发现表明强直后“慢速内吞”在质量上仍属正常:用FM1 - 43测量的这种内吞类型的速率与正常无异,并且在与该途径相关的细胞器——包被小泡、池以及突触小泡中观察到了HRP,但在微管泡结构中未观察到。在DTB处理的亮末梢中,终板电位(EPP)幅度降低,与未处理小鼠相比,对15Hz刺激的突触抑制增加;在暗末梢中,用筒箭毒碱阻断期间未观察到EPP。在亮末梢中,神经刺激诱导的FM1 - 43卸载比正常情况更慢且更不完全,在暗末梢中不发生,并且未被α - 银环蛇毒素增强。总体而言,这些结果表明在DTB诱导肌无力期间神经末梢中再循环小泡池的大小减小。这种减小发生的机制尚不确定,但越来越多的证据表明可能包括胞吐和泡内加工过程中一个或两个过程的缺陷。